Is MRTX or QYLD a better dividend investment in 2026?

MRTX currently yields 3.41% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: QYLD offers higher current income.

What is the dividend yield difference between MRTX and QYLD?

MRTX has a forward dividend yield of 3.41% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 8.51 percentage points.

Home › Compare › MRTX vs QYLD

MRTX vs QYLD: Dividend Comparison 2026

MRTX yields 3.41% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 QYLD wins by $481.00 in total portfolio value· pulled ahead in Year 10

INVESTMENT

TIME HORIZON10 years

MRTX

● Live price

3.41%

Share price

$58.70

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$24.9K

Annual income

$424.22

Full MRTX calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — MRTX vs QYLD

📍 QYLD pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MRTX	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MRTX + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MRTX pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRTX

Annual income on $10K today (after 15% tax)

$289.61/yr

After 10yr DRIP, annual income (after tax)

$360.59/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, QYLD beats the other by $4,449.83/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRTX + QYLD for your $10,000?

MRTX: 50%QYLD: 50%

100% QYLD50/50100% MRTX

Portfolio after 10yr

$25.2K

Annual income

$3,041.77/yr

Blended yield

12.09%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRTX right now

MRTX

Analyst Ratings

Buy

Hold

Consensus: Hold

Price Target

$102.10

+73.9% upside vs current

Range: $53.00 — $247.00

Altman Z

8.6

Piotroski

3/9

QYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRTX buys

QYLD buys

No recent congressional trades found for MRTX or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMRTXQYLD

Forward yield	3.41%	11.92% ✓
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$24.9K	$25.4K ✓
Annual income after 10y	$424.22	$5,659.31 ✓
Total dividends collected	$3.8K	$27.1K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: MRTX vs QYLD ($10,000, DRIP)

Year	MRTX Portfolio	MRTX Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1	$11,041	$340.72	$10,352	$1,192.36	+$689.00 → MRTX
2	$12,165	$351.56	$10,830	$1,347.57	+$1.3K → MRTX
3	$13,379	$362.03	$11,460	$1,539.07	+$1.9K → MRTX
4	$14,687	$372.10	$12,275	$1,777.84	+$2.4K → MRTX
5	$16,097	$381.77	$13,323	$2,078.95	+$2.8K → MRTX
6	$17,615	$391.04	$14,667	$2,463.34	+$2.9K → MRTX
7	$19,248	$399.92	$16,396	$2,960.57	+$2.9K → MRTX
8	$21,004	$408.41	$18,631	$3,612.97	+$2.4K → MRTX
9	$22,891	$416.50	$21,548	$4,482.15	+$1.3K → MRTX
10← crossover	$24,917	$424.22	$25,398	$5,659.31	$481.00 → QYLD

MRTX vs QYLD: Complete Analysis 2026

MRTX — Stock

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Full MRTX Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this MRTX vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRTX vs SCHD MRTX vs JEPI MRTX vs O MRTX vs KO MRTX vs MAIN MRTX vs XYLD MRTX vs JEPQ MRTX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.